You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Anti-Ret antibody [RET01] (ab1840)

CodeSizePriceAbpointsAvailability
    
 
  • -

  •   
  •   
  •   
  •  

  •  
  •  
  •  

  •  
Updating...

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »

Overview

Product name

Anti-Ret antibody [RET01]
See all Ret products (8) ...

Description

Mouse monoclonal [RET01] to Ret

Specificity

We do not know which isoform of Ret (Ret9 or Ret51) the antibody recognises.

Tested applications

IHC-P, IHC-Fr, ICC/IF, IHC (PFA fixed)more details

Cross reactivity

Reacts with

Human

Immunogen

BALB/C mice were injected with recombinant protein encoding the extreme C-terminal cytoplasmic region of the human ret oncoprotein.

Positive control

Small intestine

Properties

Form

Liquid

Storage instructions

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

Storage buffer

Preservative: 0.05% Sodium Azide
Constituents: 1% BSA, Tissue culture supernatant

Purity

Tissue culture supernatant

Primary antibody notes

Ret proto-oncogene encodes a cell surface glycoprotein belonging to a member of the receptor tyrosine kinase family and is located on chromosome 10q11.2. Ret is observed in several regions of the central nervous system; in the developing cranial nerve ganglia and a subset of cells within dorsal root ganglia, in motor neurons in the spinal cord and hindbrain.

Clonality

Monoclonal

Clone number

RET01

Isotype

IgG1

  • - Ret antibody [RET01] (ab1840)- Ret antibody [RET01] (ab1840) image (enlarge)

  • Immunocytochemistry/ Immunofluorescence - Anti-Ret antibody [RET01] (ab1840)Immunocytochemistry/ Immunofluorescence - Anti-Ret antibody [RET01] (ab1840) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab1840 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Target

Function

Probable receptor with tyrosine-protein kinase activity; important for development.

Involvement in disease

Defects in RET may be a cause of colorectal cancer (CRC) [MIM:114500].
Defects in RET are a cause of Hirschsprung disease (HSCR) [MIM:142623]. HSCR is a genetic disorder of neural crest development characterized by the absence of intramural ganglion cells in the hindgut, often resulting in intestinal obstruction. Occasionally, MEN2A or FMTC occur in association with HSCR.
Defects in RET are the cause of medullary thyroid carcinoma (MTC) [MIM:155240]. MTC is a rare tumor derived from the C cells of the thyroid. Three hereditary forms are known, that are transmitted in an autosomal dominant fashion: (a) multiple neoplasia type 2A (MEN2A), (b) multiple neoplasia type IIB (MEN2B) and (c) familial MTC (FMTC), which occurs in 25-30% of MTC cases and where MTC is the only clinical manifestation.
Defects in RET are the cause of multiple neoplasia type 2B (MEN2B) [MIM:162300]. MEN2B is an uncommon inherited cancer syndrome characterized by predisposition to MTC and phaeochromocytoma which is associated with marfanoid habitus, mucosal neuromas, skeletal and ophtalmic abnormalities, and ganglioneuromas of the intestine tract. Then the disease progresses rapidly with the development of metastatic MTC and a pheochromocytome in 50% of cases.
Defects in RET are a cause of susceptibility to pheochromocytoma (PCC) [MIM:171300]. A catecholamine-producing tumor of chromaffin tissue of the adrenal medulla or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of epinephrine and norepinephrine, is hypertension, which may be persistent or intermittent.
Defects in RET are the cause of multiple neoplasia type 2A (MEN2A) [MIM:171400]; also known as multiple neoplasia type 2 (MEN2). MEN2A is the most frequent form of medullary thyroid cancer (MTC). It is an inherited cancer syndrome characterized by MTC, phaeochromocytoma and/or hyperparathyroidism.
Defects in RET are a cause of thyroid papillary carcinoma (TPC) [MIM:188550]. TPC is a common tumor of the thyroid that typically arises as an irregular, solid or cystic mass from otherwise normal thyroid tissue. Papillary carcinomas are malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. Note=Chromosomal aberrations involving RET are found in thyroid papillary carcinomas. Inversion inv(10)(q11.2;q21) generates the RET/CCDC6 (PTC1) oncogene; inversion inv(10)(q11.2;q11.2) generates the RET/NCOA4 (PTC3) oncogene; translocation t(10;14)(q11;q32) with GOLGA5 generates the RET/GOLGA5 (PTC5) oncogene; translocation t(8;10)(p21.3;q11.2) with PCM1 generates the PCM1/RET fusion; translocation t(6;10)(p21.3;q11.2) with RFP generates the Delta RFP/RET oncogene; translocation t(1;10)(p13;q11) with TRIM33 generates the TRIM33/RET (PTC7) oncogene; translocation t(7;10)(q32;q11) with TRIM24/TIF1 generates the TRIM24/RET (PTC6) oncogene. The PTC5 oncogene has been found in 2 cases of PACT in children exposed to radioactive fallout after Chernobyl. A chromosomal aberration involving TRIM27/RFP is found in thyroid papillary carcinomas. Translocation t(6;10)(p21.3;q11.2) with RET. The translocation generates TRIM27/RET and delta TRIM27/RET oncogenes.
Defects in RET are a cause of renal adysplasia (RADYS) [MIM:191830]; also known as renal agenesis or renal aplasia. Renal agenesis refers to the absence of one (unilateral) or both (bilateral) kidneys at birth. Bilateral renal agenesis belongs to a group of perinatally lethal renal diseases, including severe bilateral renal dysplasia, unilateral renal agenesis with contralateral dysplasia and severe obstructive uropathy.
Defects in RET are a cause of congenital central hypoventilation syndrome (CCHS) [MIM:209880]; also known as congenital failure of autonomic control or Ondine curse. CCHS is a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia.

Sequence similarities

Belongs to the protein kinase superfamily. Tyr protein kinase family.
Contains 1 cadherin domain.
Contains 1 protein kinase domain.

Post-translational
modifications

Autophosphorylated on C-terminal tyrosine residues upon ligand stimulation. Dephosphorylated by PTPRJ on Tyr-905, Tyr-1015 and Tyr-1062.

Cellular localization

Membrane.

Target information above from: UniProt accessionP07949 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • C ret antibody
  • Cadherin family member 12 antibody
  • Cadherin related family member 16 antibody
  • CDHF 12 antibody
  • CDHF12 antibody
  • CDHR16 antibody
  • ELKS Fusion gene antibody
  • HSCR 1 antibody
  • HSCR1 antibody
  • Hydroxyaryl protein kinase antibody
  • MEN2A antibody
  • MEN2B antibody
  • MTC 1 antibody
  • MTC1 antibody
  • Multiple endocrine neoplasia and medullary thyroid carcinoma 1 antibody
  • Oncogene RET antibody
  • Proto oncogene tyrosine protein kinase receptor ret antibody
  • Proto-oncogene c-Ret antibody
  • Proto-oncogene tyrosine-protein kinase receptor ret antibody
  • PTC antibody
  • RET antibody
  • RET ELE1 antibody
  • Ret Proto oncogene antibody
  • RET transforming sequence antibody
  • RET_HUMAN antibody
  • RET51 antibody
  • RET9 antibody
  • tyrosine-protein kinase receptor ret antibody
see all

Anti-Ret antibody [RET01] images:

  - Ret antibody [RET01] (ab1840)

- Ret antibody [RET01] (ab1840)

ab1840 - immunohistochemistry

  Immunocytochemistry/ Immunofluorescence - Anti-Ret antibody [RET01] (ab1840)

Immunocytochemistry/ Immunofluorescence - Anti-Ret antibody [RET01] (ab1840)

ICC/IF image of ab1840 stained PC12 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab1840, used neat (Undiluted)) overnight at +4°C. The secondary antibody (green) was ab96879 Dylight 488 goat anti-mouse IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

References for Anti-Ret antibody [RET01] (ab1840)

This product has been referenced in:

  • Serra MP  et al. Ret, GFRalpha-1, GFRalpha-2 and GFRalpha-3 receptors in the human hippocampus and fascia dentata. Int J Dev Neurosci 23:425-38 (2005).Read more (PubMed: 16002253) »

See 1 publication for this product

Publishing research using ab1840? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"